METAGENOMI INC (MGX)
US59102M1045 - Common Stock
MGX gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. MGX has a great financial health rating, but its profitability evaluates not so good. MGX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
MGX had negative earnings in the past year.
In the past year MGX has reported a negative cash flow from operations.
1.2 Ratios
With a decent Return On Assets value of -20.64%, MGX is doing good in the industry, outperforming 76.99% of the companies in the same industry.
MGX has a Return On Equity of -28.91%. This is in the better half of the industry: MGX outperforms 79.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -28.91% | ||
| ROIC | N/A |
ROA(3y)-14.78%
ROA(5y)N/A
ROE(3y)-32.18%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
MGX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
MGX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for MGX remains at a similar level compared to 1 year ago.
There is no outstanding debt for MGX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
MGX has an Altman-Z score of 0.09. This is a bad value and indicates that MGX is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 0.09, MGX is in the better half of the industry, outperforming 63.89% of the companies in the same industry.
MGX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 0.09 |
ROIC/WACCN/A
WACC11.79%
2.3 Liquidity
A Current Ratio of 6.18 indicates that MGX has no problem at all paying its short term obligations.
With a decent Current ratio value of 6.18, MGX is doing good in the industry, outperforming 62.30% of the companies in the same industry.
A Quick Ratio of 6.18 indicates that MGX has no problem at all paying its short term obligations.
MGX's Quick ratio of 6.18 is fine compared to the rest of the industry. MGX outperforms 62.65% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.18 | ||
| Quick Ratio | 6.18 |
3. Growth
3.1 Past
The earnings per share for MGX have decreased strongly by -56.79% in the last year.
Looking at the last year, MGX shows a very strong growth in Revenue. The Revenue has grown by 160.21%.
EPS 1Y (TTM)-56.79%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.32%
Revenue 1Y (TTM)160.21%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-6.87%
3.2 Future
The Earnings Per Share is expected to grow by 17.62% on average over the next years. This is quite good.
Based on estimates for the next years, MGX will show a decrease in Revenue. The Revenue will decrease by -3.54% on average per year.
EPS Next Y53.64%
EPS Next 2Y22.75%
EPS Next 3Y17.62%
EPS Next 5YN/A
Revenue Next Year16.19%
Revenue Next 2Y-12.89%
Revenue Next 3Y-3.54%
Revenue Next 5YN/A
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
MGX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year MGX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as MGX's earnings are expected to grow with 17.62% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y22.75%
EPS Next 3Y17.62%
5. Dividend
5.1 Amount
No dividends for MGX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
METAGENOMI INC
NASDAQ:MGX (12/18/2024, 7:29:55 PM)
After market: 3.2 +0.09 (+2.89%)3.11
-0.28 (-8.26%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap116.38M
Analysts
Price Target
Short Float %
Short Ratio
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.64% | ||
| ROE | -28.91% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.15
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.18 | ||
| Quick Ratio | 6.18 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)-56.79%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y53.64%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)160.21%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y